Lundbeck Reports Phase IV THRIVE Trial Headline Results
Lundbeck announced headline results from the Phase IV THRIVE trial evaluating VYEPTI (eptinezumab) in patients with an inadequate response to prior CGRP-targeting preventive therapy.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.